Researchers from Canada and Australia have found that a new antibody that specifically targets cancer stem cells might be helpful in treating an aggressive type of leukemia. The therapeutic molecule created by these researchers attacks a protein, CD123, on the surface of cancer stem cells, which sustain acute myeloid leukemia (AML). This type of leukemia is difficult to treat because it does not respond well to standard chemotherapy.